Optimizing RAAS inhibition in Heart failure: Novel treatment considerations for the management of hyperkalemia
Florence, Italy - 23 May 2016
EBAC Accredited symposium held during Heart Failure 2016, Florence, Italy
View videorecording of lectures
ESC Heart Failure Congress, Florence, Italy - May 23.
The educational objectives of this symposium were:
- To understand the need for optimisation and maintenance of RAASi therapy in HFrEF;
- To understand the reasons why target doses are not reached for RAASi;
- To describe new pharmacological options for inhibiting RAAS and for management of hyperkalemia in patients with HFrEF treated with RAASi
- To describe the limitations and challenges to RAASi use in HF, in order to identify new treatment options for achieving better outcomes in HF patients.
RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis
Many HF patients are treated suboptimally, with hyperkalemia being one of the underlying reasons. Prof Faiez Zannad, Nancy, France, considers this clinical scenario, its consequences and how it can be managed.
Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure
Conventional therapies to treat hyperkalemia are associated with clinical complications. Dr. Peter van der Meer, Groningen, The Netherlands, discusses the mechanism and efficacy and safety results of two new therapeutic options that lower potassium levels: patiromer and ZS-9.
The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure?
Prof. Kenneth Dickstein considers the increase in potassium levels that arise as a consequence of blocking the renin-angiotensin system. Hyperkalemia is often a reason for not following guideline-recommended therapy, which underlines the need for novel potassium-lowering therapy.Funding
This symposium was supported by an unrestricted educational grant from AstraZeneca.In compliance with EBAC/ EACCME guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
Other news from ESC Heart Failure 2016
News • 24-5-2016
One in four patients develop heart failure within four years of first heart attack
ESC HF 2016 Data from the UK based CALIBER programme reveal that risk factors include older age, socioeconomic deprivation, and diabetes.News • 23-5-2016
No benefit of direct renin inhibitor in heart failure patients with diabetes
ESC HF 2016 Subgroup analysis of ATMOSPHERE fails to show a benefit of aliskiren as compared with enalapril in HF patients with diabetes. Combination therapy is associated with excess adverse events.News • 23-5-2016
Flu jab associated with fewer hospitalisations in patients with heart failure
ESC HF 2016 Study ends controversy over influenza vaccination in heart failure patients and provides more robust evidence for current recommendations.News • 23-5-2016
Exercise associated with longer life in patients with heart failure
ESC HF 2016 Individual patient data meta-analysis ExTraMATCH II shows that all patients benefited regardless of heart failure severity, age and gender.News • 21-5-2016
Ten commandments on optimal management of heart failure
ESC HF 2016 At the presentation of the new ESC Heart Failure Guidelines, Professor Ponikowski, Chairperson of the guidelines Task Force, summarised the guidelines as ten commandments.News • 21-5-2016
New ESC heart failure guidelines include distinct mid-range LVEF category
ESC HF 2016 A new ESC HF guideline was presented at the ESC Heart Failure Congress in Florence, and includes a new definition of HF, and updated treatment algorithms for chronic and acute HF.
3 minute education • 21-5-2016, ESC HF 2016, Florence, Italy, Adriaan Voors (Groningen, The Netherlands)
Share this page with your colleagues and friends: